Hodgkin lymphoma nodular lymphocyte-predominant · 8 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
R-CHOP Variant #23 | — | R 59 865 | 21d | ~44.4 mo | — | ~65 | ~R 3 891 219 PFS proxy · indirect | 4 |
R-EPOCH Variant #01 | — | R 13 350 | 21d | — | — | — | — | — |
R-CVP Variant #01 | — | R 12 182 | 21d | — | — | — | — | 1 |
ABVD Variant #01 | — | R 2 916 | 28d | — | — | — | — | 4 |
EPOCH Variant #01 | — | R 1 505 | 21d | — | — | — | — | — |
CHOP Variant #13 | — | R 859 | 21d | ~15.5 mo | — | ~23 | ~R 19 749 PFS proxy · indirect | 4 |
CVP (Vinblastine/Prednisolone) Variant #01 | — | R 737 | 21d | — | — | — | — | — |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~20.3 mo | — | ~4 | ~R 208 PFS proxy · indirect | 17 |
8 of 8 regimens shown